{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:50:45Z","timestamp":1785775845636,"version":"3.56.0"},"reference-count":14,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":937,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1999,6]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>: To compare lansoprazole 30\u2003mg once daily, lansoprazole 15\u2003mg once daily and ranitidine 150\u2003mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30\u2003mg once daily or ranitidine 300\u2003mg nightly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>: A double\u2010blind, parallel group, randomized multicentre study conducted in 33 centres in the UK, Eire, Sweden and Australia. Two hundred and nineteen patients with a duodenal ulcer were randomized to receive lansoprazole 30\u2003mg and 217 to receive ranitidine 300\u2003mg for 8\u2003weeks. Patients were then re\u2010randomized to receive lansoprazole 30\u2003mg (122 patients), lansoprazole 15\u2003mg (121 patients) or ranitidine 150\u2003mg (116 patients) for 12\u2003months. All patients had an endoscopically\u2010proven duodenal ulcer at baseline and were considered suitable for long\u2010term maintenance therapy to prevent relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>: Significantly more patients were healed on lansoprazole (98%) compared to ranitidine (89%) (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001, Fisher's exact test). Lansoprazole provided more rapid symptom relief than ranitidine. Lansoprazole 30\u2003mg and lansoprazole 15\u2003mg increased the probability of not relapsing in comparison to ranitidine (<jats:italic>P<\/jats:italic>\u2003=\u20030.001 and 0.06, respectively, life\u2010table analysis). Relapse rates over the 12\u2003months were lower in the lansoprazole treatment groups (lansoprazole 30\u2003mg, 5%; lansoprazole 15\u2003mg, 12%; and ranitidine, 21%; lansoprazole 30\u2003mg vs. ranitidine 150\u2003mg, <jats:italic>P<\/jats:italic>\u2003= 0.002). Symptoms were well controlled in both groups during the maintenance phase. All treatments were well tolerated with no major differences seen in adverse event profiles between treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>: Both doses of lansoprazole (30\u2003mg and 15\u2003mg) were superior to ranitidine 150\u2003mg in the prevention of duodenal ulcer relapse. Lansoprazole was superior to ranitidine in terms of symptom control and duodenal ulcer healing. Both treatments were well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1999.00533.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T22:38:48Z","timestamp":1047335928000},"page":"827-832","source":"Crossref","is-referenced-by-count":8,"title":["Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse"],"prefix":"10.1111","volume":"13","author":[{"given":"K. D.","family":"Bardhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. P. H.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Trewby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. N.","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the UK\u2010Eire Lansoprazole Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91015-X"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00025.x"},{"key":"e_1_2_6_4_2","first-page":"A78","article-title":"Lansoprazole versus ranitidine in duodenal ulcer: a French multicentre study","volume":"98","author":"Licht H","year":"1990","journal-title":"Gastroenterology"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.10.1458"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1992.tb00548.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00383.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199703000-00003"},{"key":"e_1_2_6_9_2","first-page":"43","article-title":"Interpretation of statistical methodology associated with maintenance trials","volume":"77","author":"Koch GG","year":"1984","journal-title":"Am J Med"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.2.151"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90076-N"},{"key":"e_1_2_6_12_2","first-page":"A122","article-title":"Lansoprazole for one year prevents recurrence of duodenal ulcers","volume":"106","author":"Lanza F","year":"1994","journal-title":"Gastroenterology"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)23132-3"},{"key":"e_1_2_6_14_2","first-page":"A6","article-title":"The epidemiology of Helicobacter pylori anti\u2010microbial resistance: Preliminary findings of a national survey","volume":"37","author":"Karim ON","year":"1995","journal-title":"Gut"},{"key":"e_1_2_6_15_2","unstructured":"Glupcyzinskiy GoutierS Van Den BorreC ButzierJP.Surveillance ofHelicobacter pyloriresistance to antimicrobial agents in Belgium in 1989 to 1994.Gut1995; (Suppl.2):A56A56(Abstract)."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1999.00533.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1999.00533.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1999.00533.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T21:21:33Z","timestamp":1694380893000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1999.00533.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,6]]}},"alternative-id":["10.1046\/j.1365-2036.1999.00533.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1999.00533.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}